Home›Stock Screener›Corona Remedies›Financial Statements

Corona Remedies Complete Financial Statements

4 Years of Data
2026 - 2023

In FY2026, Corona Remedies (CORONA) reported revenue ₹358 Cr, net profit ₹45 Cr and EPS ₹7.41, with a net profit margin of 12.6% and ROE of 6.0%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review CORONA P/E ratio to evaluate earnings-based valuation against sector peers.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 12.57% 2026 data
EBITDA Margin 18.44% 2026 data
Operating Margin 18.00% 2026 data
Return on Assets 3.73% 2026 data
Return on Equity 6.02% 2026 data

Balance Sheet Ratios

Current Ratio 3.59 2026 data
Equity Ratio 61.99% 2026 data
Asset Turnover 0.30 2026 data

CORONA Revenue, Net Profit & EBITDA — Year-on-Year Growth

CORONA YoY (Mar 2025 vs Mar 2026) — revenue +21.4%, net profit +40.6%, EBITDA +17.9%, expenses +21.3%. Explore Corona Remedies intrinsic worth to estimate fundamental worth using multiple valuation models.

Revenue Growth
+21.4%
Year-over-Year
Net Profit Growth
+40.6%
Year-over-Year
EBITDA Growth
+17.9%
Year-over-Year
Expense Growth
+21.3%
Year-over-Year
Assets Growth
+29.6%
Year-over-Year
Equity Growth
+23.3%
Year-over-Year
Operating Cash Flow Growth
+21.7%
Year-over-Year
Investing Cash Flow Growth
+68.5%
Year-over-Year
Financing Cash Flow Growth
-208.1%
Year-over-Year

CORONA Income Statement — Revenue, EBITDA & Net Profit

Corona Remedies revenue ₹358 Cr, EBITDA ₹66 Cr, net profit ₹45 Cr, EPS ₹7.41 (2026) — net profit margin 12.6%. For live price, earnings ratios and company overview, see CORONA stock price BSE.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Jun 2024 Dec 2024
Revenue 358 364 295 349 345 316 293 299
Expenses 291 283 240 277 278 247 242 228
EBITDA 66 81 56 72 66 69 51 70
Operating Profit Margin % 18.00% 22.00% 18.00% 20.00% 19.00% 21.00% 17.00% 23.00%
Depreciation 10 9 10 9 9 9 8 10
Interest 1 2 2 2 2 3 3 2
Profit Before Tax 55 70 44 61 55 57 39 58
Tax 9 18 12 15 14 14 9 13
Net Profit 45 52 32 46 41 43 30 45
Earnings Per Share (₹) 7.41 8.55 5.16 7.55 6.75 7.03 4.90 7.35

CORONA Balance Sheet — Assets, Liabilities & Shareholders' Equity

CORONA total assets ₹1,205 Cr, total equity ₹747 Cr, total liabilities ₹ Cr (2026) — ROE 6.0%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023
ASSETS
Total Assets 1,205 930 831 595
Current Assets 348 339 290 292
Fixed Assets 723 370 384 185
Capital Work in Progress 143 186 121 65
Investments 125 26 26 32
Other Assets 0 348 301 314
LIABILITIES
Total Liabilities
Current Liabilities 97 84 126 49
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 747 606 480 409
Share Capital 61 61 61 61
Reserves & Surplus 686 545 419 347

CORONA Cash Flow Statement — Operating, Investing & Financing

Corona Remedies operating cash flow ₹191 Cr, investing ₹-84 Cr, financing ₹-107 Cr, net cash flow ₹0 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023
Operating Activities 191 157 103
Investing Activities -84 -267 -50
Financing Activities -107 99 -45
Net Cash Flow 0 -11 8